NKGen Biotech

company

About

NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.

  • 51 - 100

Details

Last Funding Type
Seed
Last Funding Money Raised
$11M
Industries
Biotechnology,Life Science
Founded date
Jan 1, 2017
Number Of Employee
51 - 100
Operating Status
Active

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability to infinitely expand natural killer cells while significantly enhancing cytotoxicity.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$11M
NKGen Biotech has raised a total of $11M in funding over 2 rounds. Their latest funding was raised on Dec 17, 2019 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 17, 2019 Seed $11M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
NKGen Biotech is funded by 1 investors. Gaingels are the most recent investors.
Investor Name Lead Investor Funding Round
Gaingels Seed